SOD1 and amyotrophic lateral sclerosis: Indeed, different clinical trials are ongoing in ALS patients with ASO targeting SOD1, C9orf72, and FUS transcripts (ClinicalTrials.gov identifiers: NCT04856982, NCT04288856, NCT04931862, and NCT04768972).